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Modeling Marrow Damagefrom Response
Data: Evolution from Radiation Biology
to Benzene Toxicity
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Consensus principles from radiation biology were used to describe a generic set of nonlinear,
first-order differential equations for modeling toxicity-induced compensatory cell kinetics in terms
of sublethal injury, repair, direct killing, killing of cells with unrepaired sublethal injury, and
repopulation. This cellular model was linked to a probit model of hematopoietic mortality that
describes death from infection and/or hemorrhage between 5 and 30 days. Mortality data from
27 experiments with 851 dose-response groups, in which doses were protracted by rate and/or
fractionation, were used to simultaneously estimate all rate constants by maximum-likelihood
methods. Data used represented 18,940 test animals: 12,827 mice, 2925 rats, 1676 sheep, 829
swine, 479 dogs, and 204 burros. Although a long-term, repopulating hematopoietic stem cell is
ancestral to all lineages needed to restore normal homeostasis, the dose-response data from the
protracted irradiations indicate clearly that the particular lineage that is critical to hematopoietic
recovery does not resemble stemlike cells with regard to radiosensitivity and repopulation rates.
Instead, the weakest link in the chain of hematopoiesis was found to have an intrinsic
radioresistance equal to or greater than stromal cells and to repopulate at the same rates. Model
validation has been achieved by predicting the LD50 and/or fractional group mortality in 38
protracted-dose experiments (rats and mice) that were not used in the fitting of model
coefficients. Environ Health Perspect 104(Suppl 6):1293-1301 (1996)
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Introduction
An editorial in The American Statistician
by A.S.C. Ehrenberg (1), derived from
experiences with business and marketing,
insightfully describes a belief that analysis
ofmany sets ofdata (MSOD)
"seems to be the only way in which we
can produce results that are generaliz-
able, lawlike, and predictable-which in
fact hold for many sets of data ... our
concern will be with deciding what the
main effect is quantitatively, how to
model it, how consistent it is, under
what different conditions it does or does
not occur, why it arises, how it links up
with other findings, and how it can be
used in practical applications and/or in
the development oftheory."
Although we have used such practices for
nearly 20 years-in carcinogenic risk
assessments, mathematical models of acute
lethality, and marrow cell kinetics underly-
ing radiation-induced hematopoiesis-we
did not attempt to communicate those
generalized ideas outside our particular
areas of interest, nor have we stated the
essential ideas so compactly.
For mathematical models of dose-
response effects, historically there has been
a near-total reliance upon finding a simple
equation that will approximate a single set
of experimental data (SSOD) when the
numerical constants are fitted appropri-
ately. Fits to other data sets, from similar
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experimental protocols, require additional
statistical justification that the model is
acceptable and require new fitted parame-
ters. Although continued use of the same
functional form usually produces some
attempt to establish a biological interpreta-
tion ofthe underlying effects (i.e., a concep-
tual model), in general, such interpretations
usually have no fundamental validity and
ignore far more important biological fac-
tors than the few they are hypothesized to
approximate; even for those few factors,
there is a pronounced lack ofgenerality for
protracted-, fractionated-, or variable-rate
exposure protocols. Results from such exer-
cises are without substantial validity out-
side the ranges ofexperimental conditions
used and have no basis in reality when
extrapolated in terms ofdose, dose rate, or
test species/strain used.
The general domain of biologically
based or conceptual models bifurcates into
additional basic approaches. One pathway
involves assumptions, either direct or indi-
rect, that the important processes are known
in terms of specific molecular/cellular
effects, and simple factors and descriptive
models can be written accordingly. When
indirect assumptions are involved, it is
often overlooked that the conclusions
obtained from experiment-by-experiment
evaluations of the models are mandated
either by the constraints of the model or
by limitations of the particular experi-
ment used to estimate parameters. Subtle,
indirect assumptions have the hazard of
going unrecognized, perhaps even to the
researchers themselves.
Our approach formulates generalized
dose-response models in terms ofgeneric
processes: molecular effects, from a cell
kinetics perspective, and descriptions of
local and systemic reactions that may act
through cell-to-cell and/or humoral-medi-
ated effects involving hormones, chalones,
or cytokines. The dosing schedules used for
benzene experiments do not reflect adequate
protocol-dependent variability to permit
use of the MSOD approach to a degree
that would provide insight into underlying
biological mechanisms. In contrast, histori-
cal data from radiation biology do reflect
those needed variations in experimental
design. Those variations can be found at
the molecular, cellular, organ, and organ-
ism levels, and all of those structural tiers
have been considered to various degrees
in model conceptualization, coefficient
estimation, and model validation in our
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previous publications on radiation-induced
hematopoiesis (2,3). Because our maxi-
mum likelihood estimations (MLE) have
relied only upon lethality data from both
short-term and long-term irradiations,
those experiments, as summarized in
Figure 1, serve as the database to evaluate
the generic model in terms ofcells critical
to hematopoietic recovery (4,5).
Following is a briefdescription ofhow
we have formulated a generic model for
cell kinetics associated with radiation-
induced hematopoiesis and how MSODs
can be used to generalize the model and
provide insight into the fundamental
underlying mechanisms. As indicated in
Table 1, the conceptual and mathematical
models used for ionizing radiations, should
also be relevant to considerations of ben-
zene toxicity. Experimental data needed to
estimate model parameters are fragmentary.
Specifically, our intent was to use dogmatic
terms and factors (or, as a minimum condi-
tion ofacceptance those common to expert
consensus) to approximate generic processes
associated with marrow cell kinetics under-
lying acute lethality. Next, MLE methods
were used to evaluate the numerical para-
meters ofthe models and their associated
confidence bounds. This approach provides
no direct cause-effect proof that the bio-
logically based model is indeed correct in
all details, but, because enormous sets of
data, reflecting wide ranges ofvariability,
can be fitted by a common set ofevaluated
parameters that are consistent with specific
biological rate constants, it is obvious that
the model is substantially correct in behav-
ior and provides hypotheses that in turn
may be validated or modified by further
refinement ofexperimental design. In addi-
tion, we found it desirable to evaluate and
test a cell kinetics model formulated in
terms of those same nonspecific damage,
repair, and repopulation processes as derived
from colony-forming unit-spleen (CFU-S)
experiments, in contrast to the parallel
evaluation made from the generic model
and animal lethality data (i.e., the underly-
ing dependence on critical cells is not
restricted to stem or CFU-S types ofcells).
Materials and Methods
When animals are irradiated by acute
protocols, death from infection and/or
hemorrhage may occur between about 5
and 30 days postirradiation. The frequency
of death can be described by a probit
distribution function with fitted parame-
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Figure 1. Summary of data used from acute lethality experiments with protracted doses of ionizing radiations to
determine the rate constants by maximum likelihood estimation techniques in the generic cell kinetics model of
radiation-induced hematopoiesis.
Table 1. Summary of bioassays and test conditions that have been used to measure the radiomimetic toxicity of
benzene.
Tests Organisms Routes Cell types
Chromosome aberrations Bacteria Eye Bone marrow
DNAdamage Cat Inhalation Embryo
DNA inhibition Dog Intraperitoneal Fibroblast
DNA unscheduled synthesis Drosophila Intravenous Hela
Dominant lethal Frog Oral Leukocyte
Gene conversion and mitotic recombination Grasshopper Parenteral Liver
Micronucleus Guinea pig Skin Lung
Microsomal mutagenicity Hamster Subcutaneous Lymphocyte
Mutation in somatic mammalian cells Human Ovary
Mutation in microorganisms (-S9) Molds
Mutation in microorganisms (+S9) Mouse
Oncogenic transformation Nonmammals
Sex chromosome loss and disjunction Rabbit
Specific locus Rat
Sister chromatid exchanges Yeast
slope = (a7, which is the inverse standard
deviation of the frequency distribution).
The LD50 and a may be for the particular
radiation field of interest or for a standard
or reference radiation ifthere is a realistic
way ofmodeling the underlying degree of
cytopenia from the exposure ofinterest and
converting that level ofeffect back to an
equivalent reference dose of the standard
radiation associated with the LD50 and
as estimates. Depression ofneutrophils and
platelets are accepted as the proximate
cause ofdeath, but the contributing cause
ofdeath could be cytopenia of either the
terminally differentiated cells themselves,
ancestral cells, or ancestral-dependent
lineages upstream in the direction of the
undifferentiated pluripotent stem cells.
Cytopenia of a critical lineage would
result in either a deficiency of cells or
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cell-mediated cytokines. For generality, the
weakest link (i.e., lineage) was treated
generically and guided by MLE evalua-
tions, in contrast to more restrictive
assumptions. One major advantage ofthis
approach is that only one (LD50, ay) com-
bination was required for a complex experi-
ment involving different dose rates,
exposure protocols, radiation sources, etc.
(4,5). In short, only changes with respect
to the strain, species, cage care, and condi-
tions of observation required additional
LD50 and 6 values. One experiment in the
analysis comprised 26 different LD50
protocols, but all were consistent with a
common LD50 and a associated with an
"equivalent prompt dose."
In the mathematical model, cells are
compartmentalized into normal (N),
injured (I), and killed (K) populations.
Processes bywhich cells move among those
populations are modeled by first-order,
nonlinear equations. In an arbitrary vol-
ume of marrow, we call the numbers of
normal, injured, and killed cells nN, n1, and
nK, respectively. Initial conditions are nN =
no (normal before exposure), nI = 0 (no
injury before exposure) and nK = 0 (no
killing before exposure). The nO need not
be estimated because only ratios of nN, n1,
and nKrelative to nO are used. The cellular
component ofthe model is
n'N= -XNID nN-XNKD nND
+XINFIN n XNNMFNNnN [1]
nIN=-XIKDn'I-XINFINnI+ XNIDfnN [2]
nK= XNKD nN+ XIKDfnI. [3]
In these equations, X is the rate constant
that mediates movement ofcells from nor-
mal or injured states as indicated by the
first subscript to the state indicated by the
second subscript. D is dose given uni-
formly to marrow, and prime denotes the
derivative ofa cell count or dose (i.e., dose
rate) with respect to time. Factors and
terms of Equations 1 to 3 are given in
Tables 2 and 3.
The same functional form based on cel-
lular damage, repair, and repopulation was
evaluated from experimental studies on
CFU-S cells as described in a previous refer-
ence (3). Damage constants were estimated
from dose-rate data ofPuro and Clark (6).
The proliferation constant was estimated
Table 2. Summary of nonspecific processes used to write a generic cell-kinetics model for damage, repair, and
repopulation as a consequence of protracted exposure to ionizing radiations.
Process Term Definition
Sublethal injury: XNID`nN XNI = MLE constant (cells/Gy)
D'(t) =dose rate (Gy/min)
nN =cells at risk ofsublethal injury
Repair of sublethal injury: X/NF/Nnl XIN = MLE constant (cells/min)
nl= cells that can undergo repair of sublethal injury
FIN =rate-modifying factortaken to be in the range of
Equations 1.0to 2.0 and set at 1 +(no-nN-nl)/nOfrom
fits to experimental data on the mitotic cycle
Direct killing of cells: XNKD'(t)nN XNK= MLE constant (cells/Gy)
Indirect killing of cells: XIKD(t)nl X/K =MLE constant(cells/Gy)
nl=cells that have sublethal injury and can be killed by
indirect processes
Compensatory repopulation: ANNMFNNnN ANN= MLE constant(cells/min)
nN=phenotypically normal cells that can undergo mitosis
FNN =(nO- nN-nl)/nO xFIN
(nO- nN-nl)/nOcontrols proliferation rate; increases
with cytotoxicity and stops at homeostasis
M= Dirac delta function to turn on/off mitotic delay
= 0, when time (hr) >accumulated dose (Gy), and
= 1, when accumulated dose (Gy)2time (hr)
MLE Values for numerical constantsa
XNI =0.38-0.77 Gy-1; XNK= 0.12 to 0.24 Gy1;X/K =0.32 to 0.50 Gy-1; and X/N =0.022 minm1.
aRanges listed include variations assigned for species-specific DNA and radiation quality for 100 kVP X, 250 kVp
X, 137Cs, and 60Co photons. Variations due to randomness and/or analysis are not estimated in this paper. Animal
lethality studies were analyzed by maximum likelihood estimation (MLE) techniques to estimate the values for cel-
lular rate constants for processes of sublethal injury, repair, direct killing, killing of cells having unrepaired sub-
lethal injury, and compensatory repopulation. I, sublethal injury; N, normal; K, kill; 0, time at zero condition where
all cells are phenotypically normal (nN= nO = 1), the population of killed cells NK= 0; and the population of injured
cells nl= 0. Because the model permits a cell to be in one ofthree phenotypically distinct states, the subscripts on
the cellular rate constants (X) indicate movement of cells from one compartment to another, e.g., AIN indicates
repair to phenotypically normal function from an injured state. Experimental studies have typically found that visi-
ble chromosomal aberrations may occur with a frequency of about 0.1 aberration/Gy, which seems to be reason-
ably consistent with the composite action of XNI, ANK, X/K, and X/N. ForA/Nthe repair half-times would range from
15 to 31 min depending on the length of the mitotic cycle. For comparison, published half-times for repair of DNA-
double-strand breaks typically range from about 10 min to 2 hr, which includes estimates for both fast and slow
repair in various lineages of cells from different species and tissues.
Table 3. Estimates ofthe doubling time for compensatory repopulation.
Species TD(for LDlo to LD90), hr To(fortherapeuticfractions), hr To(for0.25 Gya), weeks
Swine 35 70 9
Dog 65 130 14
Mouse 70 140 14
Rat 130 260 26
Sheep 140 280 36
80.25 Gy has been used historically as a maximum for radiation workers responding to a criticality accident. XNN
(in units of min-1) values of 8.26 x 10-5 (mouse); 4.54 x 10-5 (rat); 4.23 x 105 (sheep); 1.65 x 104 (swine); and
8.89 x 10-5 (dog). In addition, the estimates given in column 4 would approximate the final degree of healing
following more serious, even nearfatal injury.
from an analysis of published values
obtained from an extensive literature review.
The repair constant was taken from the
evaluation described above for the lethality
database, but an additional normalization
was required to adjust for the shorter cycle
time ofstem/CFU-S cells in contrast to the
longer cycle for the critical cells.
Results
The two models of marrow cell kinetics
involve a) cells that are critical to compen-
satory hematopoiesis with parameters esti-
mated from MLE analysis of animal
mortality data and b) CFU-S type stem
cells with parameters fitted from in vivo
and in vitrocell-survival studies. As described







in previous publications (3,7), both models
seem to preform remarkably well according
to the foundations of their evaluations.
Clearly, the point estimates and confidence
intervals on estimated coefficients indicate
that the two cellular models are distinct
and do not merely provide dual estimates
for a common lineage.
Thirty-four experiments have been ana-
lyzed previously by MLE methods to esti-
mate cellular rate constants within the
model and are not considered suitable for
model validation considerations: 27 were
used to evaluate the photon models (5)
and 7 experiments were used to evaluate the
neutron models. The lot, 72 experiments,
resulted from an exhaustive literature
review, and selection ofthe 38 experiments
for model validation was based on a) dose
protraction by rate or fractionation in mice
or rats; b) mortality within 30 days from
the end ofthe radiation treatments (studies
were used if a few animals died from
gastrointestinal damage because it was
assumed that those same animals would
have died from marrow depression at a
later time; in contrast, studies were rejected
if even a small number ofanimals died of
marrow depression before the irradiation
schedules were completed because the min-
imum effective dose could not be deter-
mined); c) no more than 60 days between
successive dose fractions; d) equivalent
handling ofdifferent phases of a particular
experiment (e.g., uniform marrow doses
and consistency in positioning the animals;
confinement was needed to be sure animals
actually received the planned dosage);
e) adequate specifications of times or dose
rates, andf) the experiment had to be rea-
sonably successful at irradiating an ade-
quate number of animals between the
LD1o and the LD90. Overall, only about a
halfdozen studies were rejected.
The 38 experiments used to validate
the model typically reported only LD50
values without giving the actual dose-
response data. Although these studies were
not useful for unbiased estimation of
model constants, they do provide indepen-
dent tests for model validation. The 12
doses rate studies ranged from 0.0008 to
4.74 Gy/min, and the 26 fractionation
studies contained fractionations from 1.54
to 7 Gy given over periods ranging from
hours to 8 weeks. Although the conversion
of a protracted protocol to its prompt dose
equivalence is cell-lineage dependent, that
conversion for simple fractionated proto-
cols will generally produce numerically
similar estimates ofthe equivalent prompt
dose (EPD), and it is not clear which lin-
eage better explains the biology underlying
acute mortality. In contrast, complex frac-
tionation experiments and low dose-rate
studies are sensitive to lineage-specific
effects and result in different estimates for
the EPD. These lineage-dependent EPD
estimates clearly favor either a stem or a
stromal cell type model. As seen in Figure 2,
the results overwhelmingly indicate that a
2.5 -
0 3 2
radioresistant, slowly repopulating cell is
far more consistent with the biological
processes underlying acute mortality, oth-
erwise at least 50% of the distribution
should be below the abscissa value of 1.0.
The recovery to normal tissue home-
ostasis in the model is not dependent on
the insult, either physical or chemical, that
caused the injury. Instead, the recovery
associated with repair ofsublethal cellular





Figure 2. Journal publications have described LD50 estimates for protracted irradiations of mice and rats. The
dose protractions were achieved by using low-dose rates and/or dose fractionations. Because the dose-response
mortality data for these studies were not published, these experiments have not been used in our modeling
efforts, hence these 38 experiments provide 343 LD50 values and serve as a good database for model validations.
The two cell-kinetics models, i.e, one for the critical cells [rate constants determined by maximum likelihood
estimation (MLE) methods] and the CFU-S-based rate constants, were used to predict the equivalent prompt dose
associated with each protracted LD50 estimate. For each experiment, a number of protracted irradiations were
studied as part of the experimental design (an average of 343/38 = 9 per experiment). For the perfect model all
different dose protractions will yield the same estimate for the EPD. But because the EPD is lineage-specific, the
two models will make contrasting predictions for protrated protocols. For simple protracted irradiations, either
model should model the EPD accurately, and there may not be enough complexity in the experimental design to
demonstrate the difference in the two models. However, for low dose rates and/or complex fractions, the two
models will predict strikingly different EPDs, and one will have a smallervariance within a particular experiment. If
the two are statistically equal, then 50% of the cumulative distributions shown should be <1.0. As shown, the
MLE-based model reduces the variance of the experiment-specific EPD distributions by factors typically ranging
from 1.5 to 5. These comparisons were based on the 50% level of response, and the gain is usually larger if data
on the tails of the distribution function are available. Clearly, this exercise supports the idea that the critical cell
for radiation-induced hematopoiesis is radioresistant and repopulates slowly, perhaps like the experimental data
for marrow stroma or CFU-F cells.
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letely in terms of biologically related half-life, activate different mechanisms, or
:pts involving populations of cells, are associated with toxicity to nonhema-
of the mitotic cycles, mitotic delay topoietic organs may not necessarily act in
, etc. Thus, although the injury used the manner shown.
nulate the recovery shown in Figure 3 Benzene is highly mobile inside the
ue to ionizing radiations, other insults body and for simplicity may, like ionizing
5S chemical and/or surgical ablation of radiations, be expected to act primarily
arrow used to create similar injury upon cells present in the body at the time
in principle, be compensated for ofexposure. For example, Rickert et al. (8)
ling to recovery aspects of Figure 4. found the benzene half-times in different
urse, insults that have a long biological organs of male Fischer-344 rats to be 48
min over the first 9 hr ofexposure to 500
ppm by inhalation. A plot of benzene
expired in air was biphasic with t1/2 times
of 42 min and 13.1 hr. The fraction
retained with the longer half-time is less
than 5% of the exposure and therefore is
1 or 2 times the 13.1-hr half-life (i.e.,
ouse stroma 13.1-26.2 hr) is still shorter than the typi-
cal cell cycle for most multipotent cells and
their supportive stroma (3).
In regard to benzene-induced neoplasia,
nine experiments comprised six different
routes ofadministration, rats and mice as
CFU\5 test species, treatment times in the general
intervals of2, 4, 12, and 24 months, plus
variations in biological end point, dose,
0.0 0.2 0.4 0.6 0.8 1.0 and dose rate. Obviously, the data grid is
Survivingfractionofcells much too sparse to permit estimation of
numerical coefficients even ifthe appropri- 3. The models based on CFU-S data and the ate functional form of a biologically based
um likelihood estimation analysis of mortality dose-response model were known.
abeled "mouse stroma") were used to predict In regard to acute mortality from ben-
ie required for repopulation to 95% of normal
i iomeostasis from cytopenia ranging from surviv- zene toxicity, 15 experiments reflected 6
tions of about 0.001 to 0.95. These estimates different routes of administration, seven
ven by the injury to the lineages indicated and test species, and exposure times ranging
linked to the specific factors of the insults that from minutes to 7 hr. In some regards, this
d in cytopenia below normal tissue homeostasis. data grid is more sparse than the neoplasia
data, and in addition these data provide
nothing useful to view/model the effects of
dose protraction.
The cytotoxicity of colony-forming
cells (CFC) and CFU-S cells is often linked
to benzene toxicity. Seven publications
described a rather limited variety of mea-
PI / *surements for CFC and CFU-S cells, treated
by inhalation and subcutaneous injection,
at different concentrations, and concentra-
0/ > tion rates, for various periods of time, and
I- pF / a wide range of postexposure assay times.
Those data are summarized in Table 4.
The benzene experiments currently avail-
D- l able are inadequate for development of
0.0 0.2 0.4 0.6 0.8 1.0 biologically based models, except for draw-
Survivingfraction ofcells ing of some fragmentary conclusions such
4. Doubling times for CFU-S cells in mice were as thoselisted in Table 5.
ted for compensatory repopulation as described
e 2 and the text. The vectors are used to indi- repopulation by a particular cell is modeled
inges as estimated from the experimental data by ANNMFNN. The doubling time, TD,
ledinTable4. associated with a particular surviving
fraction can be estimated by TD = ln(2)/
(XNNMFNN) and is shown in Figure 4 for
a X of 0.00022 min-'. The vectors shown
in Figure 4 are estimated doubling times
from experimental data ofUyeki et al. (9)
and Cronkite et al. (12,13).
Discussion
In this paper, benzene-induced hematopoi-
etic toxicity is viewed in the broader con-
text of the spectrum of exposures that are
pancytotoxic and induce compensatory
hematopoiesis during or as a consequence
ofinjury. Chlorambucil, chloramphenicol,
chloroquine, cyclophosphamide, diethy-
lamide, griseofulvin, ethylene oxide, ioniz-
ing radiations, lysergic acid, melphalan,
methoxypsoralen, phenylbutazone, procar-






amide hydrochloride have been associated
with leukemia in humans or animals.
Several publications have concluded that
injury to both hematopoietic stem cells and
their cellular/cytokine-mediated environ-
ment can be important to acute mortality
and leukemogenesis. A number ofexperi-
mental studies have found that all marrow-
derived lineages can be regenerated from
only one cell alone surviving pluripotent
stem cell, whereas a stroma ofstrong func-
tional integrity is required to support that
regeneration. The importance ofstem and
stromal lineages, especially as potentially
related to benzene toxicity, has been
discussed previously (16-25).
In 1961, Cronkite (26) concluded
that any agent which produces marrow
aplasia is a "putative leukemogen." Later,
Adamson and Seiber (27) noted that
It is possible that a given proportion of
individuals who develop bone marrow
depression as a consequence ofchemical
exposure may ultimately develop ANLL
[acute nonlymphocytic leukemia]
regardless ofwhich agent produced the
marrow toxicity, and indeed all of the
chemicals which have been implicated as
leukemogens can be myelosuppressive.
Nevertheless, there are also chemicals
which are potent depressants of bone
marrow function but that have not been
associated with human ANLL.
Harigaya et al. (17) proposed that the role
of benzene may be more of a promoter
by forcing the pluripotent stem cells (that












































Table 4. Summary ofexperimental data oncolony-forming unit-spleen cells andcolony-forming cellsfollowing treatments with benzene.
Dosing schedule No. of Maximum con- Doserate, Dose, S(femur), Assaytime,days
Test hr/day days/week weeks exposures Route centration,ppm mg/kg-day mg/kg
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Table 4. Continued.
Dosing schedule-No. of Maximum con- Dose rate, Dose, S(femur), Assaytime,days
Test hr/day days/week weeks exposures Route centration, ppm mg/kg-day mg/kg%after administration
Cronkite etal.(14)
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Table 5. Summary ofexperimental results on benzenetoxicity to hematopoietic cells.
Study Summary
Uyeki et al. (24) Dose response: Ifthe dose rate is held constant, there seems to beonly a weak dose response for exposures of 8hr/day because ofthe limited range
of data. However, if one of the experimental points is corrected for the delay in assaytime, then the dose response becomes more consistent with
other studies.
Doublingtime/assay time: If dose and dose rate are held constant, the time delay used in the assay appears to be important. The doubling time
seems to be about 3 days for the earlyproliferation associated with a survival of about 40%.
Gill et al. (12) Dose response: Only three points are available for evaluation of a dose response, but the CFU-S cells of Gill et al. could be twice as resistant as
Uyeki et al.'s CFC cells.
Green et al. (125) Assays were made on the day that the dosing ended. These data contain both dose and dose rate variations in experimental design.
Dose response: Assays were conducted on day 0. If corrected to day 1, these results seem to be comparable to the data ofUyeki et al. Because of a
wide range of doses, the data of Green et al. show a strong dose response.
Dose rate: Astrong effect of dose rate for 6 hr/day protocol is demonstrated. Dose rate may be more biologicallysignificant than the number ofdays
exposed (when the exposure is for 4 to 6 hr/day).
Tunek et al. (26) Route of intake: These data are for sc injection; toxicity appears greater than for inhalation.
Dose response: Seems to have the same functional shape as data of Green et al.
Dose rate: Shapes of the response versus dose-rate plots are similar to those of Green et al., but the magnitudes are different. From the literature,
we have found absorption coefficients ranging from 0.28 to 0.60 (median
=0.47) for inhalation of benzene. It seems that a rigorous analysis of
absorbed fraction coupled with the dosing protocol differences used with inhalation studies are adequate to bring the Tunek et al. data in line with
the inhalation data.
Cronkite et al. (27) Dose response: Seems consistent with that of Green et al. and Tunek etal., but all doses weregiven at concentrations of 400 ppm. Data are given as
day of assay and proliferation according (day, %): 1 day, 12%; 7 days, 40%; 14days, 42%. Therefore, the doubling time seems to be about 2 days
from a survival of 10% and 4days from a survival of 20%.
Cronkite et al. (28) Dose response: Seems consistent with previous discussions, but dose rates are mostly for 300 ppm.
Doubling time: Seems to be long, probably about 40days; looks inconsistent with other studies.
Cronkite et al. (29) Doubling time: Seems to be about 2 days from a survival of 10% and 4days from a survival of 20%; times close to the previous study of Cronkite
et al. (27).
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have been exposed to leukemogenic initi-
ating agents before benzene exposure) to
undergo compensatory hematopoiesis.
Because of existing data and simple,
well-established dosimetry models, the
quantitative considerations, as described
here, have been limited to exposures
involving ionizing radiations, and the rele-
vance to benzene toxicity is implied
by analogy of molecular-, cellular-, and
organ-based processes.
As illustrated in Figure 5, our generic
model ofradiation-induced compensatory
hematopoiesis has led to a strongly sup-
ported hypothesis that cell-to-cell contact
and/or cytokine-mediated processes between
stomal and stem cells establish both the
radiosensitivity and proliferation kinetics
of the cells that are critical to hemato-
poietic recovery (28,29). Although that
hypothesis is well supported by a large
array ofstromal cell experiments, it is still
contested by some, based on the beliefthat
survival ofhematopoietic stem cells is both
necessary and sufficient for rescue from
hematopoietic syndrome. In contrast, the
model evaluations described in this paper
indicate that even though stem cell survival
is necessary, the rate-limiting considera-
tions seem to be associated with a more
radioresistant and more slowly repopulat-
ing critical cell that is consistent with char-
acteristics measured for marrow stroma




~~~ / t 3 _ ~~~~~~ Macrophages.




Ic't i kneef ,
Death--- -------------Recovery
Figure 5. Scheme based on consenus principles from radiation biology and from the results of our many model
evaluations and validations. Clearly, the supporting stromal tissues and their cytokine-mediated control of com-
pensatory hematopoiesis are obligatory to recoveryfrom toxic injury.
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